Healthcare / Drug Manufacturers - Specialty & GenericBSE
$775.00
-3.55 (-0.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $14.0M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$930M
P/E
19.7x
↓EV/EBITDA
12.7x
↑ROE
5.9%
↑Gross Margin
61.5%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.0%
FCF CAGR
—
FCF margin
-6.7%
FCF / Net income
-1.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $751.0M · net income $31.4M · FCF $-50.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $751.0M | $751.0M | $755.6M | $753.3M | $579.2M |
| Net Income | $31.4M | $31.4M | $56.5M | $55.8M | $35.6M |
| EBITDA | $77.5M | $77.5M | $98.0M | $99.8M | $76.6M |
| EPS | 26.21 | 26.21 | 47.12 | 46.49 | 29.68 |
| Gross Margin | 61.5% | 61.5% | 59.9% | 59.4% | 59.0% |
| Operating Margin | 9.9% | 9.9% | 10.1% | 8.8% | 8.2% |
| Net Margin | 4.2% | 4.2% | 7.5% | 7.4% | 6.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.11 | 0.13 | 0.15 |
| Current Ratio | 3.85 | 3.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-50.4M | $-50.4M | $19.5M | $14.0M | $32.7M |
| Returns | |||||
| ROE | 5.9% | 5.9% | 11.1% | 12.2% | 8.8% |
| Valuation | |||||
| P/E | 19.71 | 19.71 | 18.95 | 12.78 | 17.42 |
| EV/EBITDA | 12.65 | 12.65 | 11.16 | 7.35 | 8.35 |
| P/B | 1.74 | 1.74 | 2.11 | 1.56 | 1.54 |
| Growth & Yield | |||||
| Revenue Growth | -0.6% | -0.6% | 0.3% | 30.1% | — |
| EPS Growth | -44.4% | -44.4% | 1.4% | 56.6% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
37.9%
EPS terminal req.
$68.77
Spread vs growth
-82.3%
5Y implied EPS CAGR
26.0%
EPS terminal req.
$83.21
Spread vs growth
-70.4%
10Y implied EPS CAGR
17.7%
EPS terminal req.
$134.01
Spread vs growth
-62.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.0%
Start / end P/E
17.7x → 29.1x
EPS bridge
47.12 → 26.21
Residual
-28.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.